New presurgery combination therapy may improve outcomes for women with triple-negative breast cancer
The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted ...
Dec 13, 2013
0
0